Literature DB >> 22155502

Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods.

Steven A Dezell1, Yong-Oon Ahn, Jan Spanholtz, Hongbo Wang, Matthew Weeres, Scott Jackson, Sarah Cooley, Harry Dolstra, Jeffrey S Miller, Michael R Verneris.   

Abstract

Natural killer (NK) cells differentiated from hematopoietic stem cells (HSCs) may have significant clinical benefits over NK cells from adult donors, including the ability to choose alloreactive donors and potentially more robust in vivo expansion. Stromal-based methods have been used to study the differentiation of NK cells from HSCs. Stroma and cytokines support NK cell differentiation, but may face considerable regulatory hurdles. A recently reported clinical-grade, heparin-based method could serve as an alternative. How the stromal-based and heparin-based approaches compare in terms of NK cell generating efficiency or function is unknown. We show that compared with heparin-based cultures, stroma significantly increases the yield of HSC-derived NK cells by differentiating less-committed progenitors into the NK lineage. NK cells generated by both approaches were similar for most NK-activating and -inhibiting receptors. Although both approaches resulted in a phenotype consistent with CD56(bright) stage IV NK cells, heparin-based cultures favored the development of CD56(+)CD16(+) cells, whereas stroma produced more NK cell immunoglobulin-like receptor-expressing NK cells, both of which are markers of terminal maturation. At day 21, stromal-based cultures demonstrated significantly more IL-22 production, and both methods yielded similar amounts of IFN-γ production and cytotoxicity by day 35. These findings suggest that heparin-based cultures are an effective replacement for stroma and may facilitate clinical trials testing HSC-derived NK cells.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155502      PMCID: PMC3303970          DOI: 10.1016/j.bbmt.2011.11.023

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  50 in total

Review 1.  An overview of group sequential methods in longitudinal clinical trials.

Authors:  B Spiessens; E Lesaffre; G Verbeke; K Kim; D L DeMets
Journal:  Stat Methods Med Res       Date:  2000-10       Impact factor: 3.021

Review 2.  Notch signaling in the immune system.

Authors:  Gerard F Hoyne
Journal:  J Leukoc Biol       Date:  2003-10-02       Impact factor: 4.962

3.  Wnt signaling regulates hemopoiesis through stromal cells.

Authors:  T Yamane; T Kunisada; H Tsukamoto; H Yamazaki; H Niwa; S Takada; S I Hayashi
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

4.  Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.

Authors:  S Kumar; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; A Tefferi; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

5.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

6.  Hematopoietic progenitor cells grow on 3T3 fibroblast monolayers that overexpress growth arrest-specific gene-6 (GAS6).

Authors:  S P Dormady; X M Zhang; R S Basch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

7.  Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies.

Authors:  Michael J Burke; Rachel Isaksson Vogel; Sanyukta K Janardan; Claudio Brunstein; Angela R Smith; Jeffrey S Miller; Daniel Weisdorf; John E Wagner; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-08       Impact factor: 5.742

8.  Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases.

Authors:  A Ruggeri; R Peffault de Latour; M Carmagnat; E Clave; C Douay; J Larghero; J-M Cayuela; R Traineau; M Robin; A Madureira; P Ribaud; C Ferry; A Devergie; D Purtill; C Rabian; E Gluckman; A Toubert; G Socié; V Rocha
Journal:  Transpl Infect Dis       Date:  2011-04-05       Impact factor: 2.228

9.  Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.

Authors:  Rogier M Reijmers; Richard W J Groen; Annemieke Kuil; Kees Weijer; Fiona C Kimberley; Jan Paul Medema; Toin H van Kuppevelt; Jin-Ping Li; Marcel Spaargaren; Steven T Pals
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

10.  Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia.

Authors:  S Kumar; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; A Tefferi; M R Litzow
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

View more
  16 in total

1.  Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Authors:  Dandan Li; Grace Chiu; Brea Lipe; Richard A Hopkins; Jacquelyn Lillis; John M Ashton; Soumen Paul; Omar S Aljitawi
Journal:  Blood Adv       Date:  2019-04-09

2.  Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer.

Authors:  Jeannette Cany; Anniek B van der Waart; Jan Spanholtz; Marleen Tordoir; Joop H Jansen; Robbert van der Voort; Nicolaas M Schaap; Harry Dolstra
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 3.  Engineering the hematopoietic stem cell niche: Frontiers in biomaterial science.

Authors:  Ji Sun Choi; Bhushan P Mahadik; Brendan A C Harley
Journal:  Biotechnol J       Date:  2015-09-10       Impact factor: 4.677

Review 4.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

5.  Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation.

Authors:  X Wang; D A Lee; Y Wang; L Wang; Y Yao; Z Lin; J Cheng; S Zhu
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Generation of cell-derived matrices that support human NK cell migration and differentiation.

Authors:  Barclay J Lee; Everardo Hegewisch Solloa; Michael J Shannon; Emily M Mace
Journal:  J Leukoc Biol       Date:  2020-05-11       Impact factor: 4.962

7.  Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.

Authors:  Martha Luevano; Anna Domogala; Michael Blundell; Nicola Jackson; Isabela Pedroza-Pacheco; Sophie Derniame; Michelle Escobedo-Cousin; Sergio Querol; Adrian Thrasher; Alejandro Madrigal; Aurore Saudemont
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

Review 8.  Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.

Authors:  Rizwan Romee; Jeffrey W Leong; Todd A Fehniger
Journal:  Scientifica (Cairo)       Date:  2014-06-25

Review 9.  Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective.

Authors:  Cristina Eguizabal; Olatz Zenarruzabeitia; Jorge Monge; Silvia Santos; Miguel Angel Vesga; Natalia Maruri; Arantza Arrieta; Marta Riñón; Estibaliz Tamayo-Orbegozo; Laura Amo; Susana Larrucea; Francisco Borrego
Journal:  Front Immunol       Date:  2014-09-15       Impact factor: 7.561

10.  Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia.

Authors:  Emily Chiu; Martin Felices; Frank Cichocki; Zachary Davis; Hongbo Wang; Katie Tuninga; Daniel A Vallera; Tom Lee; Ryan Bjordahl; Karl Johan Malmberg; Bahram Valamehr; Jeffrey S Miller
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.